Progyny
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United Stat...
Latest News
15 hours ago · zacks.com
Progyny (PGNY) Is Up 3.85% in One Week: What You Should KnowDoes Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
6 days ago · fool.com
Progyny: 3 Key Takeaways for Long-Term InvestorsProgyny added 1.3 million covered lives for the 2027 plan year. Progyny achieved a near 100% pharmacy attach rate with new clients.
12 days ago · marketbeat.com
Progyny Q3 Earnings Call HighlightsProgyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season.
12 days ago · seekingalpha.com
Progyny, Inc. (PGNY) Q3 2026 Earnings Call TranscriptProgyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Progyny (PGNY) Tops Q3 Earnings and Revenue EstimatesProgyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.
13 days ago · globenewswire.com
Progyny, Inc. Announces Third Quarter 2026 ResultsReports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises Midpoint of Full Year Guidance Ranges NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2026 (“the third quarter of 2026”), as compared to the three-month period ended September 30, 2025 (“the third quarter of 2025” or “the prior year period”). “We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients,” said Pete Anevski, Chief Executive Officer of Progyny.
20 days ago · globenewswire.com
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to BenefitsResearch presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care
22 days ago · globenewswire.com
New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care ModelNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced improvement in their menopause symptoms, with the greatest gains observed among those who received both personalized coaching and care from menopause-trained providers.
27 days ago · globenewswire.com
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results ReportNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.
1 month ago · globenewswire.com
Progyny to Present New Menopause Research at The Menopause Society 2026 Annual MeetingNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 – 24, 2026.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PGNY